Heart Failure
Conditions
Keywords
Elderly, Frailty, Polypharmacy, Medication review, Clinical pharmacy services
Brief summary
Heart failure therapies (e.g. beta blockers) have been successful in decreasing mortality rates, as well as diminishing hospitalizations. Also, pharmacist collaboration has been shown to have a beneficial impact on heart failure related outcomes. Regardless, a high residual event rate is to be noted. In our pilot study, we wished to document whether a clinical pharmacist could still play a role in the heart failure management of an elderly inpatient heart failure population.
Interventions
OTHERheart-failure related pharmaceutical intervention
Sponsors
Universitaire Ziekenhuizen KU Leuven
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 75 years or older * diagnosis of previous or new heart failure based on signs and symptoms as defined by the 'European Society of Cardiology guidelines on acute and chronic heart failure' * diagnosis had to be confirmed by a recent echocardiogram
Exclusion criteria
* not Dutch speaking * treatment restrictions had been applied on admission
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the number of heart-failure related pharmaceutical interventions | during hospital stay (average of 14 days) |
Secondary
| Measure | Time frame |
|---|---|
| acceptance rate of the pharmaceutical interventions | during hospital stay (average of 14 days) |
| clinical feasibility of the accepted interventions | during hospital stay (average of 14 days) |
Countries
Belgium
Outcome results
None listed